DV
Dividend Vision

NAUT — Nautilus Biotechnology Inc

Nautilus Biotechnology Inc (NAUT)

Total return is -91.5% over the past 6 years, 243.5 points behind SPY at 152.0%. Its deepest 1-year drawdown was 78.1%.

Nautilus Biotechnology is a development-stage life sciences company that creates platform technology for analyzing the proteome—the full set of proteins in biological samples. The company's Nautilus Voyager Platform provides an integrated solution of instruments, reagents, consumables, and software designed to quantify and decode proteins in biological samples, and it does not currently distribute dividends. The business appeals primarily to investors interested in early-stage biotechnology and life sciences innovation rather than those seeking income.

NAUT key facts

Asset type
Stock
Asset class
Equity
Last close
$0.89
Market cap
$254,157,712
Average volume
628500.0
Beta
0.754
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.46